Newswire (Published: Wednesday, June 3, 2020, Received: Wednesday, June 3, 2020, 6:53:44 PM CDT)

Word Count: 632

2020 JUN 03 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Medical Devices Daily -- Investigators publish new report on Surgery - Prostatectomy. According to news originating from Ann Arbor, Michigan, by NewsRx correspondents, research stated, “Genomic classifiers (GC) have been shown to improve risk stratification post prostatectomy. However, their clinical benefit has not been prospectively demonstrated.”

Financial supporters for this research include Prostate Cancer Foundation, Center for Information Technology, U.S. Department of Defense, Dr. Spratt is on Janssen and Blue Earth advisory boards, Ivy Zhang is an employee of Decipher Biosciences, Tiffany Le is an employee of Decipher Biosciences, Worlanyo is an employee of Decipher Biosciences, Dr. Davicioni is an employee of Decipher Biosciences, Dr. Dabbas is an employee of Decipher Biosciences.

Our news journalists obtained a quote from the research from the University of Michigan, “We sought to determine the impact of GC testing on postoperative management in men with prostate cancer post prostatectomy. Two prospective registries of prostate cancer patients treated between 2014 and 2019 were included. All men underwent Decipher tumor testing for adverse features post prostatectomy (Decipher Biosciences, San Diego, CA). The clinical utility cohort, which measured the change in treatment decision-making, captured pre-and postgenomic treatment recommendations from urologists across diverse practice settings (n=3455). The clinical benefit cohort, which examined the difference in outcome, was from a single academic institution whose tumor board predefined ‘best practices’ based on GC results (n=135). In the clinical utility cohort, providers’ recommendations pregenomic testing were primarily observation (69%). GC testing changed recommendations for 39% of patients, translating to a number needed to test of 3 to change one treatment decision. In the clinical benefit cohort, 61% of patients had genomic high-risk tumors; those who received the recommended adjuvant radiation therapy (ART) had 2-year PSA recurrence of 3 vs. 25% for those who did not (HR 0.1 [95% CI 0.0-0.6], p=0.013). For the genomic low/intermediate-risk patients, 93% followed recommendations for observation, with similar 2-year PSA recurrence rates compared with those who received ART (p=0.93). The use of GC substantially altered treatment decision-making, with a number needed to test of only 3.”

According to the news editors, the research concluded: “Implementing best practices to routinely recommend ART for genomic-high patients led to larger than expected improvements in early biochemical endpoints, without jeopardizing outcomes for genomic-low/intermediate-risk patients.”

For more information on this research see: Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer and Prostatic Diseases, 2019;23(2):295-302. Prostate Cancer and Prostatic Diseases can be contacted at: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA. (Nature Publishing Group - http://www.nature.com/; Prostate Cancer and Prostatic Diseases - http://www.nature.com/pcan/)

The news correspondents report that additional information may be obtained from D.E. Spratt, Dept. of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States. Additional authors for this research include J. Marascio, J. Zhang, E.J. Trabulsi, T. Le, W.S. Sedzorme, W.H. Beeler, E. Davicioni, B. Dabbas, D.W. Lin, J.L. Gore, M. Bloom, M. Mann, J.R. Mark, A. Calvaresi, J.L. Godwin, P. McCue, M.D. Hurwitz, W.K. Kelly and L.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/s41391-019-0185-7. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher’s contact information for the journal Prostate Cancer and Prostatic Diseases is: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

US Department of Defense
University of Michigan

Industries

Healthcare
      Healthcare Technology

Places

North America
United States
Americas
California
Michigan
New York
San Diego
Ann Arbor
New York City

Subjects

Science and Technology
      Scientific Research
            Medical Research
      Technology
            Healthcare Technology
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Healthcare Technology
            Medical Research
      Medical Specialties and Practices
            Surgery
      Treatments and Therapies
            Surgery
Politics and Government
      Government Agencies (U.S.)
            Department of Defense